I'm Praveen Suthrum. After 13 years of building and running NextServices, a healthcare technology/management company, the challenges and opportunities in the industry leap out at me. I also get early access to industry trends and changes.

Whether you are seeking to start or grow your healthcare business, my weekly insights will make you spot opportunities and stay on top of your game. It'll help you think differently about healthcare.

Two ways people consistently describe what I write: 
"insightful" and "thought-provoking".

Sign-up for my newsletter to get early and exclusive access to material that I don't write about elsewhere.

A DNA stool test reminds me of Google's self-driving car

A DNA stool test reminds me of Google's self-driving car

I sat in a Google self-driving car back in 2012...when it was still a Toyota Prius. See the pic below. Neither I nor the car look this way anymore. 

Praveen Suthrum - Google self-driving car.jpg

The big gadget on top of the car is the LiDAR sensor. That device fires rapid pulses of light all the time and all around to detect objects in the vicinity. It’s what self driving cars use to navigate.

Back then LiDARs cost $75,000. It wasn’t accurate enough to ensure people won’t get killed on the road. Google spent $200,000 to assemble each autonomous car. Most car companies called the effort an unreasonable but “cute, research project”.

Every 2 years after that, the LiDAR doubled up in accuracy and dropped by half in price. So did the Google's self-driving car.

A stool test to detect colon cancer

FDA approved stool DNA technology in 2014 - the product is called Cologuard. Major cancer screening guidelines and quality measures now include the product. Medicare and other insurers cover its hefty price point.

On their website, if you click on “How effective is Cologuard?”, an image loads up showing that Cologuard found 92% of colon cancers (per a study involving ~10,000 people).

That’s an 8% miss rate. The company is quick to point that false positives and false negatives occur with their product. 

At The GI Roundtable conference in April 2019, Jason Dominitz, MD, MHS, National Program Director for Gastroenterology in the Veterans Health Administration asked the audience this question. What risk are you willing to take for your patient?

The question might as well apply to Cologuard. 

It’s not my place to comment on clinical aspects of Cologuard. I’m just the biller who knows how to get my clients paid correctly for various gastroenterology procedures. 

But as a curious technologist, I can’t help but note that...

It cost $2.7 billion to fully sequence the human genome in 2003. And today, it costs $200 to do so.

I learn that it’ll soon be a penny to sequence the whole genome. It'll open new dimensions in digital biology, including editing genes. 

I can't help but think along the same lines with Cologuard. 

Screening with a scope is linear - one doctor, one patient at a time. Screening via a test is non-linear or data-based. You can scale the test exponentially with no dependency on humans.

With digital biology, we move from analog to digital, taking us into the realm of software engineering. We can now talk about data that can be read, analyzed and possibly programmed.

We are then moving from linear to exponential.

Exponential growth of Cologuard

See these graphs. This one shows their impressive, consistent quarterly revenue growth.

Quarterly revenue growth of Cologuard.png

This one shows the number of physicians who ordered the test for the first time. Observe the exponential spike in 2018.

Physicians ordering Cologuard the first time.png

With more tests, Exact Sciences (the maker of Cologuard) will have more data. With more data, the test will tend to get more and more accurate. 

As of end of 2018, Exact Sciences performed 1 million tests.

Surely, they'll do more. 

What if Cologuard recruits a vast global community of bio-programmers to somehow reduce the miss rate? Or even catch the miss rate as it occurs?

It’s not unthinkable if you’ve ever used the Waze app - a GPS navigation software. Waze even lets you know where cop cars are standing based on what other drivers tell the app.

Catching the miss rate as it occurs is also not unimaginable. That's how Facebook's AI pulls down inappropriate live videos - even as they occur.

What I worry about...

I worry...

  • That referrals of screening colonoscopy, the bread-and-butter of several GI doctors, will decline

  • That insurance reimbursements for traditional CRC screening will keep getting lower. To the point of no return

  • That the forces of DNA sequencing and AI (check ai4gi classifying polyps) will intersect at some point in the near future.

  • That ancillary revenues from biopsies (from CRC) will also go away because now we will exactly know which polyps are cancerous

  • That GI doctors performing below quality benchmarks will be left behind

Guess the price of LiDAR today?

Today (7 years later), the Google car is called Waymo. They call it "the world's most experienced driver".

Waymo got cooler. See below. The little black thing on top is the LiDAR.

 Making a car autonomous used to cost $200K/car.

Then it dropped to $100K/car.

Then to $50K/car.

Now, it hovers around $1,000/car. 

The LiDAR scanner costs $50. To remind you, the scanner cost more than 1,000x back then.

It’s expected to cost $10 and sneak into the gadgetry that occupies your smartphone.

Unlike the LiDAR scanner, Cologuard continues to be priced high. More than screening colonoscopy - at $649 - may be because Medicare and others are willing to pay for it. That's more than sequencing a whole genome! But even a hefty healthcare system can't stop an exponential curve.

Exponential changes don't just happen because of one trend or technology. It's because various trends collide and accelerate the doubling.

Should I say this or is it apparent? GI and several other specialties are in the middle of massive disruption. It just depends on which side of the disruption we choose to be. 

All product and company names are trademarks or registered trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.

When healthcare goes awry. From drugs to disruption

When healthcare goes awry. From drugs to disruption